skip to main content

Bisphosphonate atypical femoral fracture — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardMusculoskeletal TherapeuticsBisphosphonate atypical femoral fractureGPhC CRA

A woman taking risedronate for seven years develops persistent dull thigh pain without trauma. No imaging has yet been performed. Which action best reflects MHRA advice?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Evaluate for an incomplete femur fracture and review continuing risedronate

During bisphosphonate treatment, new thigh, hip or groin pain should prompt evaluation for an incomplete femur fracture. If an atypical fracture is suspected, discontinuation should be considered while the patient is evaluated, based on the individual benefit–risk assessment. The source specifically recommends contralateral examination after a femoral shaft fracture; the revised question does not overextend that wording.

Reference: MHRA Drug Safety Update, Bisphosphonates and atypical femoral fractures: https://www.gov.uk/drug-safety-update/bisphosphonates-atypical-femoral-fractures